Toxicological and toxicokinetic analysis of angiotensin (1-7) in two species

Journal of Pharmaceutical Sciences

Volumn 101, Issue 1, 2012, Pages 373-380

  Mordwinkin, Nicholas M ^a   Russell, Jared R ^a   Burke, Angela S ^c   Dizerega, Gere S ^b   Louie, Stan G ^a,b   Rodgers, Kathleen E ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c WIL RESEARCH LABORATORIES   (United States)

Author keywords

Analysis; LC MS; Peptides; Pharmacokinetics; Toxicology

Indexed keywords

ANGIOTENSIN[1-7];

ARTICLE; BLOOD LEVEL; BONE MARROW SUPPRESSION; DRUG METABOLISM; FEMALE; MALE; NONHUMAN; PLASMA HALF LIFE; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPRAGUE DAWLEY RAT; TOXICOKINETICS;

EID: 82255179512     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22730     Document Type: Article

References (19)

1. Lavoie JL, Sigmund CD. 2003. Minireview: Overview of the renin-angiotensin system-An endocrine and paracrine system endocrinology. Endocrinology 144(6):2179-2183.
2. Rodgers KE, Xiong S, diZerega GS. 2003. Effect of angiotensin II and angiotensin (1-7) on hematopoietic recovery after intravenous chemotherapy. Cancer Chemother Pharmacol 51(2):97-106.
3. Rodgers KE, Xiong S, diZerega GS. 2002. Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemother Pharmacol 49(5):403-411.
4. Abiko M, Rodgers KE, Campeau JD, Nakamura RM, diZerega GS. 1996. Alterations of angiotensin II receptor levels in full-thickness excisional wounds in rat skin. Wound Repair Regen 4(3):363-367.
5. Takeda H, Katagata Y, Hozumi Y, Kondo S. 2004. Effects of angiotensin II receptor signaling during skin wound healing. Am J Pathol 165:1653-1662.
6. Rodgers KE, Roda N, Felix JE, Espinoza T, Maldonado S, diZerega G. 2003. Histological evaluation of the effects of angiotensin peptides on wound repair in diabetic mice. Exp Dermatol 12(6):784-790.
7. Rodgers KE, Ellefson DD, Espinoza T, Maulhardt H, Roda N, Maldonado S, diZerega G. 2005. Fragments of Nle3-angiotensin(1-7) accelerate healing in dermal models. J Pept Res 66(Suppl 1):41-47.
8. Rodgers KE, Xiong S, Espinoza T, Roda N, Maldonado S, diZerega GS. 2000. Angiotensin II increases host resistance to peritonitis. Clin Diagn Lab Immunol 7:635-641.
9. Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. 2004. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 383:45-51.
10. Rodgers KE, Xiong S, Steer R, diZerega GS. 2000. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells 18:287-294.
11. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. 2003. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100(14):8258-8263.
12. Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, Gembardt F, Kellett E, Martini L, Vanderheyden P, Schultheiss HP, Walther T. 2005. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111(14):1806-1813.
13. Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. 2009. Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res 15(23):7398-7404.
14. Yamada K, Iyer SN, Chappell MC, Ganten D, Ferrario CM. 1998. Converting enzyme determines plasma clearance of angiotensin-(1-7). Hypertension 32:496-502.
15. Allred AJ, Diz DI, Ferrario CM, Chappell MC. 2000. Pathways for angiotensin-(1-7) metabolism in pulmonary and renal tissues. Am J Physiol Renal Physiol 279:F841-F840.
16. 5-ANG II-infused rats. Am J Physiol Renal Physiol 296:F1067-F1071.
17. Ulm EH, Vassil TC. 1982. Total serum angiotensin converting enzyme activity in rats and dogs after enalapril maleate (MK-421). Life Sci 30(14):1225-1230.
18. Rodgers KE, Oliver J, DiZerega G. 2006. Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemother Pharmacol 57: 559-568.
19. Mow T, Poulsen K, Nielsen AH, Baandrup U, Pedersen HD. 1999. Species differences in expression of angiotensin II receptors and angiotensin-converting enzyme in human, canine and rat mitral valve leaflets. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 124(1):11-17.